Skip to main content
PMC home page
Frontiers in Psychology logoLink to Frontiers in Psychology
. 2022 Feb 3;12:768748. doi: 10.3389/fpsyg.2021.768748

CYP2D6 Genetic Variation and Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis

Yanisa Wannasuphoprasit 1, Stig Ejdrup Andersen 2, Maria J Arranz 3,4, Rosa Catalan 4,5, Gesche Jurgens 2, Sanne Maartje Kloosterboer 6, Henrik Berg Rasmussen 7,8, Anjali Bhat 1, Haritz Irizar 1, Dora Koller 9,10, Renato Polimanti 9,10, Baihan Wang 1, Eirini Zartaloudi 1, Isabelle Austin-Zimmerman 1,11,†, Elvira Bramon 1,11,12,13,*,†
PMCID: PMC8850377  PMID: 35185676

Abstract

Background

Antipsychotic-induced weight gain is a contributing factor in the reduced life expectancy reported amongst people with psychotic disorders. CYP2D6 is a liver enzyme involved in the metabolism of many commonly used antipsychotic medications. We investigated if CYP2D6 genetic variation influenced weight or BMI among people taking antipsychotic treatment.

Methods

We conducted a systematic review and a random effects meta-analysis of publications in Pubmed, Embase, PsychInfo, and CENTRAAL that had BMI and/or weight measurements of patients on long-term antipsychotics by their CYP2D6-defined metabolic groups (poor, intermediate, normal/extensive, and ultra-rapid metabolizers, UMs).

Results

Twelve studies were included in the systematic review. All cohort studies suggested that the presence of reduced-function or non-functional alleles for CYP2D6 was associated with greater antipsychotic-induced weight gain, whereas most cross-sectional studies did not find any significant associations. Seventeen studies were included in the meta-analysis with clinical data of 2,041 patients, including 93 poor metabolizers (PMs), 633 intermediate metabolizers (IMs), 1,272 normal metabolizers (NMs), and 30 UMs. Overall, we did not find associations in any of the comparisons made. The estimated pooled standardized differences for the following comparisons were (i) PM versus NM; weight = –0.07 (95%CI: –0.49 to 0.35, p = 0.74), BMI = 0.40 (95%CI: –0.19 to 0.99, p = 0.19). (ii) IM versus NM; weight = 0.09 (95% CI: –0.04 to 0.22, p = 0.16) and BMI = 0.09 (95% CI: –0.24 to 0.41, p = 0.60). (iii) UM versus EM; weight = 0.01 (95% CI: –0.37 to 0.40, p = 0.94) and BMI = –0.08 (95%CI: –0.57 to 0.42, p = 0.77).

Conclusion

Our systematic review of cohort studies suggested that CYP2D6 poor metabolizers have higher BMI than normal metabolizers, but the data of cross-sectional studies and the meta-analysis did not show this association. Although our review and meta-analysis constitutes one of the largest studies with comprehensively genotyped samples, the literature is still limited by small numbers of participants with genetic variants resulting in poor or UMs status. We need further studies with larger numbers of extreme metabolizers to establish its clinical utility in antipsychotic treatment. CYP2D6 is a key gene for personalized prescribing in mental health.

Keywords: CYP2D6, antipsychotic-induced weight gain, antipsychotic, weight gain, pharmacogenetic, personalized medicine, mental health

Introduction

Antipsychotic drugs are an important treatment option for psychotic disorders including schizophrenia, bipolar disorder, and other psychoses (Taylor et al., 2021). Antipsychotics have been shown to improve psychotic symptoms with fewer relapses in the first year (Leucht et al., 2012) and reduce excess mortality in people living with schizophrenia (Taipale et al., 2018, 2020). However, their adverse effects, including extrapyramidal side effects in typical antipsychotics and metabolic side effects in atypical antipsychotics, can have an impact on physical health and quality of life and contribute to drug discontinuation (Lieberman et al., 2005; Leucht et al., 2013).

Antipsychotic-induced weight gain is a frequently reported adverse drug reaction, particularly to second-generation antipsychotics (Miyamoto et al., 2012), leading to increased risk for cardiovascular diseases, diabetes and some types of cancer (Newcomer, 2005; Osborn et al., 2013). These are some of the key reasons for the 10–20-year average reduction in life expectancy observed in people with schizophrenia (Chesney et al., 2014; Galderisi et al., 2021). The mechanisms of antipsychotic-induced weight gain include genetic, biological and psychosocial factors that are not fully understood. Indeed, the propensity to develop weight gain varies between individuals and different drugs and is dose-related (Müller and Kennedy, 2006; Simon et al., 2009; Tek et al., 2016). One approach to understand this inter-individual variability is through pharmacogenetic studies investigating how genetic variation can influence treatment response and tolerability.

The Cytochrome P450 family of liver enzymes include, among others, CYP1A2, CYP2D6, CYP2C19, and CYP3A4, which are essential for the metabolism of many commonly prescribed medications (Guengerich, 2008). CYP2D6 is involved with the metabolic pathway of approximately 40% of antipsychotic drugs, including aripiprazole, risperidone, haloperidol, chlorpromazine (Fleeman et al., 2011; Cacabelos et al., 2013). CYP2D6 is a highly polymorphic gene with more than 100 known functional variants including null or increased function alleles with deletions or duplications respectively, as well as other variants resulting in reduced enzyme activity (Sim and Ingelman-Sundberg, 2013; Nofziger et al., 2020). Based on the combination of these alleles, participants can be categorized into four CYP2D6 phenotypic groups: poor metabolizers (PMs), intermediate metabolizers (IMs), normal metabolizers, (NMs), and ultra-rapid metabolizers (UMs) (Caudle et al., 2020). Therefore, PMs and IMs have higher drug plasma concentrations and may be more likely to experience adverse drug reactions, while UMs show lower drug plasma concentrations and potentially poorer efficacy (Ingelman-Sundberg, 2005; Nofziger et al., 2020).

CYP2D6 genetic variation is shown to impact antipsychotic plasma concentrations in previous pharmacokinetic studies of aripiprazole, haloperidol and risperidone, where antipsychotic dosage and duration of treatment were controlled for (Van Der Weide and Van Der Weide, 2015; Sychev et al., 2017; Belmonte et al., 2018). Therefore, the varying plasma concentrations could influence the likelihood of patients developing adverse effects, including weight gain (Kloosterboer et al., 2021), and consequently, CYP2D6 gene testing could contribute to inform appropriate antipsychotic prescribing in clinical settings (Taylor et al., 2021). In fact, CYP2D6 genetic testing for several antipsychotics, including haloperidol, aripiprazole and risperidone, has already been recommended in clinical guidelines by the Dutch Pharmacogenetics Working Group (DPWG) (Swen et al., 2011).

Previous systematic reviews and meta-analyses investigating the putative relationship between CYP2D6 metabolic status and antipsychotic adverse effects highlighted that there is limited primary research, yielding inconclusive results (Lett et al., 2012; Maruf et al., 2020). The relationship between CYP2D6 genotype and antipsychotic related weight gain has not been examined in a meta-analysis, despite being one of the most common adverse reactions to antipsychotics. Therefore, we here aim to conduct the first systematic review and meta-analysis to investigate whether CYP2D6 genetic variation influences weight gain in people taking antipsychotic treatment.

Materials and Methods

Literature Search

We searched in Pubmed, Embase, PsychInfo, and CENTRAL databases for original peer-reviewed papers published in English from January 1995 to April 2021 (both inclusive), using the following search terms: ‘(Cytochrome* or CYP* or P450 or CYP2D6) AND (antipsychotic* or neuroleptic* or risperidone or olanzapine or thioridazine or perphenazine or fluphenazine or zuclopenthixol or haloperidol or chlorpromazine or clozapine or quetiapine or ziprasidone or benperidol or methotrimeprazine or pimozide or sulpiride or trifluoperazine or amisulpride or sertindole or zotepine or aripiprazole) AND (genot* or allel* or pharmacogenetic* or pharmacokinetic*) AND (BMI or weight or obes* OR body mass index or ADRs or ADR or adverse drug reactions)’. Of note, this list of medications was chosen from Drug Bank (Wishart et al., 2006), the Maudsley Prescribing guideline (Taylor et al., 2021) and review papers (Baptista et al., 2005; Fleeman et al., 2011; Leucht et al., 2013) as medications that could be metabolized via CYP2D6 pathway or have weight gaining effects. Additionally, we performed a Google Scholar search for review articles that looked at pharmacogenetics of antipsychotics, focusing on CYP2D6 polymorphisms and metabolic side effects and examined their reference lists for additional relevant articles.

Inclusion Criteria and Data Extraction

The inclusion criteria were: (1) randomized control trials or observational studies conducted in patients taking antipsychotic drugs; (2) genotyped one or more CYP2D6 alleles; and (3) BMI and/or weight of the participants were recorded. The studies had to meet all three inclusion criteria to be considered eligible to be included in the systematic review and/or meta-analysis.

The titles and abstracts were initially assessed by two independent reviewers. Full text articles were assessed for eligibility, and the authors of eligible records were contacted for unpublished data when necessary.

Some authors published open-source data with weight and BMI by CYP2D6 metabolic groups. Several studies published weight and BMI by CYP2D6 allelic variants, while others provided us their database with all the CYP2D6 allelic variants of each participant. In the latter, we classified participants into CYP2D6 metabolic groups from their star alleles using the consensus method, which was standardized for consistency between the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG) (Caudle et al., 2020). Each star allele is assigned an activity score: the activity score for a non-functional allele (e.g., *3, *4 and *5; gene deletion) is 0, for a reduced function allele (e.g., *41) is 0.5 (except that of *10 which is 0.25), for a normal function allele (e.g., *1 and *2) is 1, and for an increased function allele (e.g., *1xN and *2xN; gene duplication) is more than 1 (Supplementary Table 1). The activity score of each of the star alleles is then summed to give a total activity score for an individual. Lastly, the individual is assigned into CYP2D6 metabolic groups according to their total activity score (Supplementary Table 2).

Statistical Analysis

We performed a meta-analysis with the Review Manager 5.2 software (The Cochrone Collaboration, 2014), using an inverse variance-weighted random effects model. A random effects model was chosen due to the moderate heterogeneity between the included studies. The comparisons of standardized mean differences of weight (kg) and BMI (kg/m2) were made using Hedges’ adjusted model between the following groups (i) PMs versus NMs, (ii) IMs versus NMs, (iii) UMs versus NMs, and (iv) PMs and IMs combined versus NMs and UMs combined. Where more than one weight and/or BMI measurements per subject were available, the readings at the end of the follow-up period were included. Tau2, chi2, and I2 tests were performed to assess heterogeneity between studies.

Additionally, we performed the following sensitivity analyses: choice of statistical test (random or fixed effects model), age group (adult or children and adolescents), relevant diagnoses (schizophrenia or other diagnoses) and medications taken (risperidone monotherapy or other medications). We did the analyses on the comparisons with the highest number of included studies for weight and BMI.

To find evidence of publication bias, we plotted a Funnel plot and performed an Egger’s regression (Egger et al., 1997) in the analyses that included more than ten studies, using Jamovi software (Version 1.6), an interface based on R package Metafor (Viechtbauer, 2010; The Jamovi Project, 2021).

Results

Literature Search

The literature search yielded 517 records. We excluded 174 duplicates, 103 review articles and 69 conference abstracts. Subsequently, 171 reports were assessed by two reviewers and 17 studies were included in the meta-analysis and 12 in the systematic review (see Figure 1 for the PRISMA flow diagram. Template taken from Page et al., 2021). The reasons for excluding the records included insufficient information on weight or BMI (Inada et al., 2003; Plesnicar et al., 2006; Subuh Surja et al., 2008) and ineligible study population such as healthy volunteers receiving a single drug dose (Sun et al., 2019) or schizophrenic patients with acute episodes who were on antipsychotic medication for less than one month before weight measurement (Vandenberghe et al., 2015). Some had genotyped some CYP2D6 single nucleotide polymorphisms (SNPs) but, unfortunately, these selected SNPs did not allow us to call for CYP2D6 alleles and classify participants into CYP2D6 metabolic groups (Lee et al., 2012).

FIGURE 1.

FIGURE 1

Open in a new tab

PRISMA flow diagram.

Seven studies were included in the systematic review, but not in the meta-analysis, because they only published the conclusion of the analysis onto their paper, but not the analysis itself. Meanwhile, 11 studies in the meta-analysis were not included in the systematic review as their primary research outcomes were not weight and/or BMI.

Systematic Review Findings

Twelve studies were included in the systematic review, six of which were cohort observational studies (Table 1), while the others were cross-sectional observational studies (Table 2). All six cohort studies showed evidence supporting the influence of CYP2D6 genetic variation on antipsychotic-induced weight gain.

TABLE 1.

The characteristics of the cohort observational studies included in the systematic review.

Study N Ethnicity Mean age ± SD (range) in years Gender, % Male Antipsychotics Mean dose ± SD (range) Duration of treatment Diagnosis CYP2D6 alleles genotyped
Lu et al., 2021 76 Not reported (China) 45 (35–54) 100% Risperidone 5 (2–6) mg/day 8 weeks Schizophrenia *2, *10, and *65
Jallaq et al., 2021 277 European descents (83.3%), African–Caribbean (10.8%) 14.3 ± 2.4 (6.0–19.6) 34.3% Aripiprazole Maximum dose 30 mg/day Not reported Mood disorder (e.g. bipolar, major depressive disorder) *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *14, *15, *17, *18, *19, *20, *40, *41, *42, and *44.
Nussbaum et al., 2014 81 Not reported (Romania) 15.7 (9–20) 46% Risperidone, Aripiprazole, Olanzapine Not reported At least 18 months Schizophrenia, bipolar disorders *4
Correia et al., 2010 45 European descents (97.8%) 8.7 ± 4.30 (3–21) 75.6% Risperidone 1.3 ± 0.7 (0.5–3) mg/day At least 12 months Autism *3, *4, *5, *6 and gene duplication.
Lane et al., 2006 123 Asian (Hans Chinese) 34.0 ± 9.7 55.3% Risperidone 4.0 ± 1.4
mg/day (at end point – day 42)		 42 days Schizophrenia with acute exacerbations *10 (188-C/T)
Ellingrod et al., 2002 11 European descents 35.6 ± 5.5 100% Olanzapine 14.3 ± 3.4
mg/day		 Mean 13.8± 13.6 months Schizophrenia *3 and *4
Open in a new tab

TABLE 2.

The characteristics of the cross-sectional observational studies included in the systematic review.

Study N Ethnicity Mean age ± SD (range) in years Gender, % Male Antipsychotics Mean dose ± SD (range) Duration of treatment Diagnosis CYP2D6 alleles genotyped
Sukasem et al., 2018 89 Not reported (Thailand) 10.0 (8.9–13.4) 91.0% Risperidone 1 (0.5–1.5) mg/day 63.9 (40.4–83.5) months Autism-spectrum disorder *4, *10, *5, *41 and gene duplication.
Dos Santos-Júnior et al., 2016 120 Not reported (Brazil) 13 ± 3.1 (8–20) 81.7% Risperidone 0.04 ± 0.03
mg/kg/day		 Not reported Mental and behavioral disorders *10 (c.100C > T)
Dodgen et al., 2015 24 European descents (58.3%), African-Caribbean (41.7%) 32.9 ± 12.4 (18–61) 66.7% Risperidone 3.9 ± 1.8
mg/day		 Not reported Any psychiatric disorders using an array with multiple SNPs for CYP2D6 (at least 10 alleles genotyped)
Suzuki et al., 2014 66 Not reported (Japan) 37.4 ± 15.0 51.5% Risperidone 4.8 ± 2.5
mg/day		 At least 4 weeks Schizophrenia *5 and *10
Vanwong et al., 2014 86 Not reported (Thailand) 9.4 ± 3.6 83.7% Risperidone 0.9 ± 0.8
mg/day		 At least 2 weeks,
37.8 ±
20.3 months		 Autism *4, *5, *10, and *11
Mihara et al., 2000 101 Not reported (Japan) 48 ± 11 30.7% Haloperidol 12 mg/day (all subjects) At least 2 weeks Schizophrenia *5 and *10
Open in a new tab

Among the cohort studies identified, Jallaq et al. (2021) reported CYP2D6 phenotypes to be significantly associated with BMI percentile change (p = 0.038) in children and adolescents taking aripiprazole, although the direction of the effect was unclear from the box plot available. Other significant factors seen to influence BMI change included duration of aripiprazole treatment and the number of CYP2D6 substrate medications taken by each subject. Another study (Correia et al., 2010) in children and adolescents taking risperidone found significantly lower increase in BMI of 4.8% and in waist circumference of 5.8% in UMs compared to NMs, supporting a link between CYP2D6 metabolic phenotypes and antipsychotic-induced weight gain. However, this was contradicted by the findings in PMs whose increase in waist circumference appeared lower compared to NMs by 4%, possibly due to the small number of PM subjects.

The rest of the cohort studies looked at specific CYP2D6 alleles, rather than CYP2D6 metabolic phenotypes. Ellingrod et al. (2002) identified greater BMI percentage change in adult participants taking olanzapine with CYP2D6*3 or CYP2D6*4 alleles (more than 125%) compared to those without the non-functional alleles (just below 115%; p = 0.0097), although this study was limited by a small sample size of 11 participants. Supporting this study was a study by Nussbaum et al. (2014) who followed children and adolescents on risperidone, aripiprazole and olanzapine for 18 months, and identified significantly increased BMI in those with CYP2D6*4 alleles from 6 months follow-up onward. By the end of the 18-month follow-up, subjects with one non-functional allele had a mean BMI increase of 8.12 kg/m2, which was significantly greater than that of subjects with two wild-type copies (2.27 kg/m2; p < 0.001). Additionally, Lane et al. (2006) found evidence that adult patients receiving risperidone with CYP2D6 *1/*10 and CYP2D6 *10/*10 genotypes had a significantly higher weight of 1.138 kg and 0.799 kg respectively at the end of 42-day follow-up period, compared to CYP2D6 *1/*1 carriers. This was confirmed by Lu et al. (2021) who also investigated CYP2D6*10 and suggested that this variant was associated with weight gain and increased BMI compared to CYP2D6*2 and CYP2D6*65 carriers. Reports from the same study also suggested that those with the C2851T allele (the defining allele for CYP2D6*2) had less weight gain. However, it appeared that the overall trend for all participants from Lu et al.’s (2021) study ended up with lower weight and BMI after four and eight weeks of initiating risperidone, which contradicted previous literature that supported the weight gaining effect of risperidone (Muench and Hamer, 2010; Leucht et al., 2013; Avrahami et al., 2021).

On the contrary to the findings from cohort observational studies, only one out of six cross-sectional observational studies found a significant association between CYP2D6 metabolic phenotypes and antipsychotic-induced weight gain (Table 2). Dos Santos-Júnior et al. (2016) identified a significant association between the number of CYP2D6*10 alleles and occurrence of obesity in children and adolescents receiving risperidone. All cross-sectional studies involved risperidone in either adults or children and adolescents except one (Mihara et al., 2000). Of note, Vanwong et al. (2014) and Sukasem et al. (2018) could have some partial sample overlap.

Meta-Analysis Findings

Seventeen studies were included in the meta-analysis and their characteristics are summarized in Table 3. In total, we identified 83 PMs, 566 IMs, 1137 extensive metabolizers and 30 UMs with weight measurements available and 71 poor, 451 intermediate, 875 normal, and 21 UMs with BMI measurements available.

TABLE 3.

Characteristics of the studies included in the meta-analysis.

Study N Ethnicity Mean age ± SD (range) in years Gender, %Males CYP2D6 Genotyping Diagnosis Antipsychotic drugs Outcomes Summary of findings
Jürgens et al., 2020 290 Not reported (Denmark) 41.4 (30–53) 54.3% *3, *4, *5, *6 and gene duplication. Schizophrenic spectrum Various antipsychotics, e.g., aripiprazole, risperidone, and clozapine. Dose and treatment duration at baseline not reported. BMI and weight N/A
Jallaq et al., 2021 277 European descents (83.3%), African-Caribbean (10.8%) 14.3 ± 12.5 (6.0–19.6) 34.3% *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *14, *15, *17, *18,*19, *20, *40, *41, *42, and *44. Mood disorders (bipolar mania, major depressive disorder or disruptive mood dysregulation disorder) Aripiprazole. 56.7% were on 5 mg or more of Aripiprazole. Duration of treatment 367.8 ± 464.7 days Weight BMI percentage change was associated with CYP2D6 phenotype groups.
Kloosterboer et al., 2021 40 European descents (Dutch origin) (78.6%) Median age 9.7 ± 5.3 (6–18). 76.2% *3, *4, *5, and *41 Autism-spectrum disorder Risperidone. Median dose = 1.0 ± 0.5 mg per day. Median duration of treatment = 5.7 ± 4.8 months BMI and weight N/A
Ortega-Vázquez et al., 2021 48 Not reported (Mexico) 38.65 ± 10.53 58.3% rs28371706, rs1065852, rs3892097, rs35742686 and gene duplication Schizophrenia, Schizoaffective disorder and bipolar disorder. Clozapine. Mean dose 188.75 ± 141.83 (10-700) mg/day for at least 6 months. BMI and weight N/A
Arranz et al., 2019 163 Not reported (Spain) 47.6 ± 13.6 45.9% *2, *3, *4, *5, *6, *9, *10, *35, *41 and gene duplication Schizophrenia, Schizoaffective and delusional disorder. Various antipsychotics, e.g., clozapine, risperidone, and olanzapine. Mean olanzapine dose-equivalent 11.0 ± 6.4 mg/day. Treatment duration at baseline not reported. BMI and weight. N/A
Kiss et al., 2019 93 Not reported (Hungary) 31 (18–65) 44.1% *3, *4, *5, *6, *10, and *41 Schizophrenia, bipolar disorders Aripiprazole. Mean dose 15 mg/d (5–30 mg/d) for at least 4 weeks. Weight N/A
Akamine et al., 2017 41 Not reported (Japan) 36.4 ± 12.5. 24.4% *1, *2, *5, and *10 Schizophrenia 100–600 mg per day of Clozapine for at least 4 weeks Weight N/A
Sychev et al., 2017 54 European descents (Russian and Tatar) 43.6 ± 13.5 49.4% *4 Schizophrenia Haloperidol monotherapy. Mean dose 12.6 mg/day (SD 4.2 mg/day). Weight N/A
Ivanova et al., 2016 475 European descents (100%) 40 (17–80) Not reported *3 and *4 Schizophrenia Multiple drugs: Haloperidol, Chloroprotixene, Chloropromazin, Trifluoperazin, Clopiksol, and Risperidone. BMI and weight N/A
Dos Santos-Júnior et al., 2016 120 Not reported (Brazil) 13.0 ± 3.1 (8–20) 81.7% *10 Mental and behavioral disorders Risperidone. Mean dose 21.1 mg/day (SD 1.3 mg/day). Mean duration of treatment 25.9 ± 27.2 months BMI The presence of *10 allele was associated with occurrence of obesity.
Nussbaum et al., 2014 81 Not reported (Romania) 15.7 (9–20) 46% *4 Schizophrenia, Bipolar disorders Either: Risperidone, Aripiprazole, or Olanzapine. Dose and treatment duration not reported. BMI was recorded at 0, 3, 6, 12, and 18 months. No significant results at 0–3 months. Those with one *4 allele had significantly higher BMI than those with no * alleles at 6–18 months.
Suzuki et al., 2014 66 Not reported (Japan) 37.4 ± 15.0 51.5% *5 and *10 Schizophrenia Risperidone. Mean dose 4.8 ± 2.5 mg/day for 4 weeks. Weight No statistically significant difference in weight between those with 2 mutant alleles, those with 1 mutant allele and those with wild type alleles.
Roke et al., 2013 46 European descents (98%) 14.7 ± 2.1 (10 to 19). 100%. *3, *4 *5, *6 and gene duplication. Autism spectrum disorder or Disruptive behavior disorder as well as any psychiatric disorder. Risperidone. Mean dose 1.6 mg/day or 0.026 mg/kg. Mean duration of treatment 4.4 ± 2.4 years. BMI and weight N/A
Bigos et al., 2011 178 118 European descents and 60 African–Caribbean Not reported 73% *4 Schizophrenia 7.5–30 mg of Olanzapine per day. Treatment duration not reported. BMI and weight N/A
Mihara et al., 2003 85 Not reported (Japan) 44.6 ± 14.4. 31.8% *2, *3, *4, *5, and *10 Schizophrenia No medication for at least 2 weeks followed by 3 mg of Risperidone twice a day for at least 2 weeks. Weight N/A
Ellingrod et al., 2002 11 European descents 35.5 ± 5.4 100% *3 and *4 Schizophrenia Olanzapine. Mean dose 14.2 ± 3.3 (ranges: 7.5–20) mg/day. Mean duration of treatment 13.8 ± 12.9 months. BMI Those with *1/*3 or *1/*4 genotype had significant BMI increase compared to those with *1/*1.
Mihara et al., 2000 101 Not reported (Japan) 48 ± 11. 30.7% *3, *4, *5, and *10 Schizophrenia 12 mg/day of Haloperidol for at least 2 weeks. Weight N/A
Open in a new tab

All the characteristics reported, including age, gender and antipsychotic medications, are of the whole study population of the papers. *N/A means the main outcomes of the studies were other side effects of antipsychotic medications rather than weight or BMI. The relationship between CYP2D6 genetic variation and weight or BMI was not published in these studies. Unpublished data was acquired from contacting the authors.

Meta-Analysis Comparing CYP2D6 Poor Metabolizers and Normal Metabolizers

Ten studies were included in this comparison (Figure 2). Nussbaum et al. (2014) and Dos Santos-Júnior et al. (2016) only had the data for BMI available, while Kiss et al. (2019) and Jallaq et al. (2021) only had weight measurements. 93 PMs and 1025 NMs were identified in total. Weight and BMI were not significantly different between PMs and NMs with the standardized mean difference (SMD) for weight = –0.07 (95% CI: –0.49 to 0.35, p = 0.74) and SMD for BMI = 0.40 (95% CI: –0.19 to 0.99, p = 0.19). The results of the I2 test for both weight (60%) and BMI (75%) point at substantial heterogeneity between the primary studies.

FIGURE 2.

FIGURE 2

Open in a new tab

Forest plots comparing (A) standardized mean weight differences (B) standardized mean BMI differences between Poor metabolizers and Normal metabolizers. Random effects model and inverse variance method were use. CI, confidence interval; df, degree of freedom; N, number of participants; SD, standard deviation; SMD, standardized mean difference.

Meta-Analysis Comparing CYP2D6 Intermediate Metabolizers and Normal Metabolizers

Sixteen studies with weight data for 566 IMs and 1108 NMs and BMI data for 451 IMs and 875 NMs were included in this comparison (Figure 3). The analysis showed no significant difference in weight and BMI between IMs and NMs (Weight: SMD = 0.09, 95%, CI: –0.04 to 0.22, p = 0.16; BMI: SMD = 0.09, 95% CI: –0.24 to 0.41, p = 0.60). The I2 of the heterogeneity test for weight was 23%, suggesting low to moderate heterogeneity, whereas that of BMI was 84%.

FIGURE 3.

FIGURE 3

Open in a new tab

Forest plots comparing (A) standardized mean weight differences (B) standardized mean BMI differences between Intermediate metabolizers and Normal metabolizers. Random effects model and inverse variance method were use. CI, confidence interval; df, degree of freedom; N, number of participants; SD, standard deviation; SMD, standardized mean difference.

Meta-Analysis Comparing CYP2D6 Ultra-Rapid and Normal Metabolizers

The data for UMs were limited. We were able to include five studies with only a total of 505 NMs and 29 UMs (Figure 4). There was no evidence of weight or BMI differences in UMs compared to NMs (weight; SMD = 0.01, 95% CI: –0.37 to 0.40, p = 0.94 and BMI; SMD = –0.08, 95% CI: –0.57 to 0.42, p = 0.77).

FIGURE 4.

FIGURE 4

Open in a new tab

Forest plots comparing (A) standardized mean weight differences (B) standardized mean BMI differences between Ultra-rapid metabolizers and Normal metabolizers. Random effects model and inverse variance method were use. CI, confidence interval; df, degree of freedom; N, number of participants; SD, standard deviation; SMD, standardized mean difference.

Grouped Analyses, Sensitivity Analyses, and Tests for Publication Bias

To increase statistical power, we conducted a secondary analysis to compare between group 1: PMs and IMs combined (N = 661) and group 2: NMs and UMs combined (N = 1167). No statistically significant differences were found (Figure 5).

FIGURE 5.

FIGURE 5

Open in a new tab

Forest plots comparing (A) standardized mean weight differences (B) standardized mean BMI differences between Poor metabolizers and Intermediate metabolizers combined compared to Normal metabolizers and Ultra-rapid metabolizers combined. Random effects model and inverse variance method were use. CI, confidence interval; df, degree of freedom; N, number of participants; SD, standard deviation; SMD, standardized mean difference.

We also performed sensitivity analyses for these group analyses to evaluate the following variables; choice of statistical test (random or fixed effects model), age (adult or children and adolescents), diagnoses (schizophrenia or other diagnoses), and medications (risperidone monotherapy or other medications). None of the sensitivity analyses yielded significant results (Table 4). This was consistent with the main analyses and, therefore, supporting the robustness of the main analyses.

TABLE 4.

Table summarizing results from sensitivity analyses for the comparison of standardized mean weight/BMI between (1) PM and IM combined versus (2) NM and UM combined.

Sensitivity analysis category Weight
 BMI
Studies PM/IM NM/UM Standardized mean difference [95% CI] P-value I-squared Studies PM/IM NM/UM Standardized mean difference [95% CI] P-value I-squared
Original (random effects) 14 661 1167 0.05 [–0.06, 0.16] 0.36 10% 11 522 895 0.14 [–0.17, 0.45] 0.37 84%
Fixed effects 14 661 1167 0.05 [–0.05, 0.14] 0.34 10% 11 522 895 0.07 [–0.04, 0.19] 0.19 84%
Adult 11 500 963 0.02 [–0.10, 0.13] 0.77 5% 7 404 725 0.01 [–0.12, 0.13] 0.91 0%
Children and adolescents 3 161 204 0.15 [–0.10, 0.40] 0.25 13% 4 118 170 0.45 [–0.64, 1.54] 0.42 94%
Schizophrenia 9 453 870 0.01 [–0.12, 0.15] 0.86 19% 6 395 687 0.01 [–0.13, 0.14] 0.92 10%
Other diagnosis 5 208 297 0.16 [–0.02, 0.34] 0.08 0% 5 127 208 0.37 [–0.53, 1.26] 0.42 92%
Risperidone monotherapy 4 74 124 –0.16 [–0.47, 0.15] 0.31 0% 3 90 117 −0.08 [–0.37, 0.20] 0.57 0%
Other medications 10 587 1043 0.08 [–0.04, 0.20] 0.19 20% 8 432 778 0.24 [–0.15, 0.64] 0.23 88%
Open in a new tab

Finally, we assessed publication bias using a Funnel plot and an Egger’s regression analysis. We did the analysis in the comparisons that included more than ten studies, which were of comparisons of SMDs of (1) weight between IMs and NMs (coefficient = –0.310, p = 0.757; Figure 6A), (2) BMI between IMs and NMs (coefficient = 0.050, p = 0.960; Figure 6B), (3) weight between PMs and IMs combined versus NMs and UMs combined (coefficient = –0.155, p = 0.877; Figure 7A), and (4) BMI between PMs and IMs combined versus NMs and UMs combined (coefficient = 0.055, p = 0.956; Figure 7B). These Egger’s regression analysis did not show evidence of publication bias. The funnel plots for the comparisons with weight measurements were symmetrical indicating no evidence of publication bias, whereas those for BMI appeared asymmetrical with fewer studies on the significant results side, suggesting that there may be a possible bias or other factors influencing the symmetry. However, the asymmetry seen is on the opposite side to what one would expect if there is publication bias. It is worth noting that 11 out of the 17 included studies did not publish their weight or BMI data. This data was kindly shared with us upon request to the authors. Hence, inclusion of these primary papers may reduce the publication bias. We did not test publication bias for the rest of the group comparisons since there were only between three and eight primary studies thus limiting statistical power to detect publication bias.

FIGURE 6.

FIGURE 6

Open in a new tab

Funnel plots with studies comparing (A) standardized mean weight differences (B) standardized mean BMI differences between Intermediate metabolizers and Normal metabolizers.

FIGURE 7.

FIGURE 7

Open in a new tab

Funnel plots with studies comparing (A) standardized mean weight differences (B) standardized mean BMI differences between Poor metabolizers and Intermediate metabolizers combined compared to Normal metabolizers and Ultra-rapid metabolizers combined.

Discussion

To our knowledge, this study is the first comprehensive systematic review and meta-analysis of the literature on the relationship between CYP2D6 genetic variation and antipsychotic-induced weight gain. Considering that weight gain is one of the most common adverse effects in second-generation antipsychotics and CYP2D6 enzyme plays a key role in the metabolism of many antipsychotics, there were surprisingly only five papers that specifically investigated this relationship. Weight gain can affect quality of life and more research on this topic will help us understand how genetic testing can be used to guide antipsychotic prescribing.

In our systematic review, all cohort studies found evidence that genetic variation resulting in decreasing CYP2D6 function was associated with antipsychotic-induced weight gain, and increased function alleles were associated with lower gain in weight or BMI. However, the systematic review of cross-sectional studies and our meta-analysis did not support this and found no significant differences between CYP2D6 metabolic groups upon weight or BMI. This inconsistency within the literature available could be due to the size and quality of primary studies and highlights the importance of careful study designs that account for the frequency of relevant genetic variants as well as other relevant variables that could influence weight gain.

Some of the cohort studies investigated specific CYP2D6 allelic variants rather than CYP2D6 metabolic groups and found associations between specific CYP2D6 alleles and antipsychotic-induced weight gain. This was mostly supported by previous literature since several sources (Gaedigk et al., 2008; Hicks et al., 2017; Nofziger et al., 2020) coincided to find enough pharmacokinetic evidence to conclude that CYP2D6*3 and CYP2D6*4 are non-functional alleles, whereas CYP2D6*10 is a reduced-function allele. These alleles result in increased plasma antipsychotic concentrations and may therefore increase the likelihood of developing antipsychotic-induced weight gain. Meanwhile, CYP2D6*2 is believed to result in normal metabolism, which contradicts the findings in Lu et al. (2021).

In this meta-analysis, we did not find evidence of a relationship between CYP2D6 genetic variation and antipsychotic-induced weight gain. The comparison of weight and BMI for PMs included only 93 patients in this group and high heterogeneity between primary studies, which limited statistical power. The small sample size reflected the low prevalence of PMs in general population ranging from 1% in East Asians to 7% in individuals of European descent (Ozawa et al., 2004). Correspondingly, the number of UMs included in the analysis was even smaller and making the comparison most likely underpowered. Considering the comparisons for IMs with more than 400 participants in this group, power was not a concern, and our data showed no evidence of a change on antipsychotic-induced weight gain in IMs. Several factors could have confounded the analyses and we will discuss these in the following paragraphs.

Firstly, the demographic characteristics of the participants varied considerably between studies, including age groups, ethnicities, male to female ratio and the diagnoses, and this contributed to the high heterogeneity found between primary studies as indicated by the sensitivity analysis (Table 4). The group analysis with BMI measurements showed high heterogeneity with I-squared of 84% (Figure 5B). Further subgroup analyses have shown high heterogeneity in the following subgroups: the children and adolescents age group, those having diagnoses other than schizophrenia and those taking medications other than risperidone, whereas their counterpart subgroups did not show evidence of heterogeneity. These analyses provide evidence that these studies are the source of the significant heterogeneity between studies for analyses involving BMI measurements.

Previous research (Strassnig et al., 2007; Gebhardt et al., 2009) shows that female gender and younger age are risk factors for developing antipsychotic-induced weight gain. While African Americans appear to have increased risk of antipsychotic-induced weight gain compared to individuals of European descent, East Asians show reduced risk (Chan et al., 2013; Tek et al., 2016). When comparing weight gain in children and adolescents, it is also recommended to consider their baseline weight and height and methods like using a z-score should be considered (Martínez-Ortega et al., 2013). Unfortunately, we could not control for these variables in our meta-analysis and if more studies were available, meta-regressions accounting for ethnicity, age, sex, drugs, and other key variables should be conducted.

Secondly, some studies in the meta-analysis (Dodgen et al., 2015; Jallaq et al., 2021) performed extensive genotyping using CYP2D6 arrays, whereas others (Bigos et al., 2011; Nussbaum et al., 2014; Dos Santos-Júnior et al., 2016) only genotyped one or very few single nucleotide polymorphisms. Although these are the most common non-functional and reduced function alleles in European and North American population, the studies in question may have missed other allelic variants that could influence CYP2D6 metabolic activity and mislabeled participants as NMs, leading to fewer numbers of poor, intermediate, or UMs identified (Owen et al., 2009; Gaedigk et al., 2017).

Thirdly, the hypothesis of this study was based on pharmacokinetic studies that found evidence supporting the effect of CYP2D6 gene variation on plasma concentration of many, but not all, antipsychotic medications (Brockmöller et al., 2002; Kubo et al., 2007; Dahl, 2012). These pharmacokinetic findings may not necessarily translate to varying degrees or incidences of adverse effects (Simon et al., 2009). One reason is that antipsychotics can be metabolized using several metabolic pathways, involving many Cytochrome P450 enzymes (Urichuk et al., 2008). The main metabolic pathway for a particular drug may involve other CYP450 enzymes besides CYP2D6 and, furthermore, certain antipsychotics such as clozapine and olanzapine may inherently have more propensity to cause weight gain (Lett et al., 2012; Leucht et al., 2013). Therefore, antipsychotic choice can greatly influence the amount of weight gain measured. In addition to the drug choice, duration of treatment (Spina and De Leon, 2007; Tek et al., 2016). Jones et al. (2001) and Brandl et al. (2016) suggested that weight gain plateaued off at 6–9 months after initiating antipsychotics. This could mean that, in some primary studies, the duration of treatment may have been too short to observe weight gain, while in other studies weight change within individuals may not be easily distinguishable in long-term antipsychotic use. Furthermore, it is common for participants who take antipsychotics to be co-prescribed other psychotropic medications, many of which are CYP2D6 substrates or inhibitors and can influence the level of antipsychotics in the plasma (Spina and De Leon, 2007; Taylor et al., 2018). Another limitation of our meta-analysis (and the literature identified more broadly) is that there were not enough studies to conduct single drug analyses and that we had to combine studies across several antipsychotics, which differ in their influence on weight and dependency of CYP2D6. Similarly, it was impossible to capture the effect of antipsychotic dose which is likely to be important on the extent of weight change, but current evidence is still limited, as summarized in Anath et al. (2003) review.

Finally, the mechanism of antipsychotic-induced weight gain is complex and involves both genetic and lifestyle factors. The mechanism is polygenic with strong genetic influence as demonstrated in a monozygotic twin study (Theisen et al., 2005). There has been extensive evidence on the role of HTR2C gene (De Luca et al., 2007; Wallace et al., 2011) and many genome-wide association studies have identified candidate genes for antipsychotic induced weight gain, supporting the importance of genetics in what is a complex gene-drug interaction (Müller and Kennedy, 2006; Brandl et al., 2016; Maciukiewicz et al., 2019). Considering lifestyle factors, many people with antipsychotic-induced weight gain concurrently have disturbances in other metabolic markers, including hypercholesterolemia, raised HbA1c or plasma glucose. It is believed that one mechanism is an increase in leptin plasma levels, a hormone that increases appetite and food intake (Reynolds and McGowan, 2017). Future research should account for lifestyle factors influencing weight and consider background genetic variation, for example, by using polygenic risk scores of antipsychotic-induced weight gain.

In conclusion, our systematic review of cohort studies suggested that CYP2D6 PMs taking antipsychotics have higher BMI than NMs. Of note, these four studies were designed to control variables affecting weight and BMI and included one of the largest and most comprehensively genotyped samples. However, the rest of the systematic review in cross-sectional studies, and the meta-analysis, did not find an influence of CYP2D6 genetic variation on antipsychotic-induced weight or BMI gain. This literature is still limited by the small number of participants with genetic variants resulting in PM status and the high heterogeneity between studies. In addition, BMI and weight gain can be influenced by environmental and genetic factors, which cannot all be accounted for in the same way across the literature. Overall, our review suggested that there may be some association between CYP2D6 gene variation and antipsychotic-induced weight gain, but current evidence is not sufficient to confirm the relationship. Therefore, prospective studies with large samples, especially of PMs, are needed to explore this relationship further. Nevertheless, CYP2D6 remains the primary candidate gene for genetic testing to guide antipsychotic prescribing as recommended by the Dutch Pharmacogenetics Working Group (Swen et al., 2011). With further research and collaborative effort to incorporate pharmacogenetics into clinical environment, CYP2D6 testing may prove useful to prevent or mitigate weight gain and other adverse effects in people needing antipsychotic treatment.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Author Contributions

YW, IA-Z, and EB designed the study and the statistical analysis plan. YW conducted the search and statistical analysis, with support from IA-Z and EB. SA, GJ, HR, MA, RC, and SK provided the additional data. YW wrote the manuscript, with contributions from SA, MA, RC, GJ, SK, HR, AB, HI, DK, RP, BW, EZ, IA-Z, and EB. YW, SA, MA, RC, GJ, SK, HR, AB, HI, DK, RP, BW, EZ, IA-Z, and EB reviewed the manuscript and made substantial contributions to the writing and interpretation. All the authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Funding

This study was supported by Medical Research Council doctoral studentships awarded to IA-Z. BW was supported by the China Scholarship Council-University College London Joint Research Scholarship. HI has received funding from the European Union’s Horizon 220 Research and Innovation Program under the Marie Skłodowska-Curie grant agreement no. 747429 and is currently supported by a grant from the National Institute of Allergy and Infectious Diseases, National Institutes of Health. AB was supported by a Medical Research Council doctoral studentship (MR/N013867/1). EB has received the following grant funding that supported this work: National Institute of Health Research UK (NIHR200756); Mental Health Research UK John Grace QC Scholarship 2018; BMA Margaret Temple Fellowship 2016; Medical Research Council New Investigator and Centenary Awards (G0901310 and G1100583), MRC (G1100583); NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyg.2021.768748/full#supplementary-material

Click here for additional data file. (705.8KB, docx)

References

  1. Akamine Y., Sugawara-Kikuchi Y., Uno T., Shimizu T., Miura M. (2017). Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms. Ann. Clin. Biochem. 54 677–685. 10.1177/0004563216686377 [DOI] [PubMed] [Google Scholar]
  2. Anath J., Venkatesh R., Burgoyne K., Augustines D., Corpuz V., Gunatilake S. (2003). Weight gain associated with atypical antipsychotic drugs: mechanisms and management. Expert Rev. Neurother. 3, 59–68. 10.1586/14737175.3.1.59 [DOI] [PubMed] [Google Scholar]
  3. Arranz M. J., Gonzalez-Rodriguez A., Perez-Blanco J., Penadés R., Gutierrez B., Ibañez L., et al. (2019). A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments. Transl. Psychiatry 9:177. 10.1038/s41398-019-0511-519 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Avrahami M., Peskin M., Moore T., Drapisz A., Taylor J., Segal-Gavish H., et al. (2021). Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone. J. Psychopharmacol. 35 1134–1140. 10.1177/02698811211008592 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Baptista T., Mendoza S., De, Beaulieu S., Bermúdez A., Martinez M. (2005). The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. Metab. Syndr. Relat. Disord. 2 290–307. 10.1089/MET.2004.2.290 [DOI] [PubMed] [Google Scholar]
  6. Belmonte C., Ochoa D., Román M., Saiz-Rodríguez M., Wojnicz A., Gómez-Sánchez C. I., et al. (2018). Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin. Pharmacol. Toxicol. 122 596–605. 10.1111/bcpt.12960 [DOI] [PubMed] [Google Scholar]
  7. Bigos K. L., Bies R. R., Pollock B. G., Lowy J. J., Zhang F., Weinberger D. R. (2011). Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol. Psychiatry 16 620–625. 10.1038/mp.2011.38 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brandl E. J., Tiwari A. K., Zai C. C., Nurmi E. L., Chowdhury N. I., Arenovich T., et al. (2016). Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample. Pharmacogenomics J. 16 352–356. 10.1038/tpj.2015.59 [DOI] [PubMed] [Google Scholar]
  9. Brockmöller J., Kirchheiner J., Schmider J., Walter S., Sachse C., Müller-Oerlinghausen B., et al. (2002). The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin. Pharmacol. Ther. 72 438–452. 10.1067/mcp.2002.127494 [DOI] [PubMed] [Google Scholar]
  10. Cacabelos R., Cacabelos P., Aliev G. (2013). Genomics of schizophrenia and pharmacogenomics of antipsychotic drugs. Open J. Psychiatry 3 46–139. [Google Scholar]
  11. Caudle K. E., Sangkuhl K., Whirl-Carrillo M., Swen J. J., Haidar C. E., Klein T. E., et al. (2020). Standardizing CYP 2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group. Clin. Transl. Sci. 13 116–124. 10.1111/cts.12692 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chan L. F., Zai C., Monda M., Potkin S., Kennedy J. L., Remington G., et al. (2013). Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics 14 1273–1281. 10.2217/PGS.13.127 [DOI] [PubMed] [Google Scholar]
  13. Chesney E., Goodwin G. M., Fazel S. (2014). Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 13 153–160. 10.1002/wps.20128 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Correia C. T., Almeida J. P., Santos P. E., Sequeira A. F., Marques C. E., Miguel T. S., et al. (2010). Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J. 10 418–430. 10.1038/tpj.2009.63 [DOI] [PubMed] [Google Scholar]
  15. Dahl M.-L. (2012). Cytochrome P450 Phenotyping/Genotyping in patients receiving antipsychotics. Clin. Pharmacokinet. 41 453–470. 10.2165/00003088-200241070-200241071 [DOI] [PubMed] [Google Scholar]
  16. De Luca V., Mueller D., de Bartolomeis A., Kennedy J. (2007). Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int. J. Neuropsychopharmacol. 10 697–704. 10.1017/S1461145707007547 [DOI] [PubMed] [Google Scholar]
  17. Dodgen T. M., Eloff A., Mataboge C., Roos L., van Staden W., Pepper M. S. (2015). Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort. Appl. Transl. Genomics 5 40–46. 10.1016/j.atg.2015.05.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Dos Santos-Júnior A., Henriques T. B., de Mello M. P., Della Torre O. H., Paes L. A., Ferreira-Neto A. P., et al. (2016). Pharmacogenetics of risperidone and cardiovascular risk in children and adolescents. Int. J. Endocrinol. 2016 1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Egger M., Smith G. D., Schneider M., Minder C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315 629–634. 10.1136/BMJ.315.7109.629 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ellingrod V. L., Miller D., Schultz S. K., Wehring H., Arndt S. (2002). CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr. Genet. 12 55–58. 10.1097/00041444-200203000-00008 [DOI] [PubMed] [Google Scholar]
  21. Fleeman N., Dundar Y., Dickson R., Jorgensen A., Pushpakom S., McLeod C., et al. (2011). Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J. 11 1–14. 10.1038/tpj.2010.73 [DOI] [PubMed] [Google Scholar]
  22. Gaedigk A., Sangkuhl K., Whirl-Carrillo M., Klein T., Steven Leeder J. (2017). Prediction of CYP2D6 phenotype from genotype across world populations. Genet. Med. 19 69–76. 10.1038/gim.2016.80 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Gaedigk A., Simon S., Pearce R., Bradford L., Kennedy M., Leeder J. (2008). The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83 234–242. 10.1038/sj.clpt.6100406 [DOI] [PubMed] [Google Scholar]
  24. Galderisi S., De Hert M., Del Prato S., Fagiolini A., Gorwood P., Leucht S., et al. (2021). Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: a Delphi expert consensus study. Eur. Psychiatry 64 1–24. 10.1192/j.eurpsy.2020.115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gebhardt S., Haberhausen M., Heinzel-Gutenbrunner M., Gebhardt N., Remschmidt H., Krieg J. C., et al. (2009). Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J. Psychiatr. Res. 43 620–626. 10.1016/J.JPSYCHIRES.2008.11.001 [DOI] [PubMed] [Google Scholar]
  26. Guengerich F. P. (2008). Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol. 21 70–83. [DOI] [PubMed] [Google Scholar]
  27. Hicks J. K., Sangkuhl K., Swen J. J., Ellingrod V. L., Müller D. J., Shimoda K., et al. (2017). Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin. Pharmacol. Ther. 102 37–44. 10.1002/cpt.597 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Inada T., Senoo H., Iijima Y., Yamauchi T., Yagi G. (2003). Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatr. Genet. 13 163–168. 10.1097/00041444-200309000-00005 [DOI] [PubMed] [Google Scholar]
  29. Ingelman-Sundberg M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5 6–13. 10.1038/sj.tpj.6500285 [DOI] [PubMed] [Google Scholar]
  30. Ivanova S. A., Filipenko M. L., Vyalova N. M., Voronina E. N., Pozhidaev I. V., Osmanova D. Z., et al. (2016). CYP1A2 and CYP2D6 gene polymorphisms in schizophrenic patients with neuroleptic drug-induced side effects. Bull. Exp. Biol. Med. 160 687–690. 10.1007/S10517-016-3250-4 [DOI] [PubMed] [Google Scholar]
  31. Jallaq S. A., Verba M., Strawn J. R., Martin L. J., Delbello M. P., Ramsey L. B. (2021). CYP2D6 phenotype influences aripiprazole tolerability in pediatric patients with mood disorders. J. Child Adolesc. Psychopharmacol. 31 56–62. 10.1089/cap.2020.0058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Jones B., Basson B. R., Walker D. J., Crawford A. M. K., Kinon B. J. (2001). Weight change and atypical antipsychotic treatment in patients with schizophrenia. J. Clin. Psychiatry 62 (Suppl. 2), 41–44. [PubMed] [Google Scholar]
  33. Jürgens G., Andersen S. E., Rasmussen H. B., Werge T., Jensen H. D., Kaas-Hansen B. S., et al. (2020). Effect of routine cytochrome P450 2D6 and 2C19 genotyping on antipsychotic drug persistence in patients with schizophrenia: a randomized clinical trial. JAMA Netw. Open 3:e2027909. 10.1001/jamanetworkopen.2020.27909 [DOI] [PubMed] [Google Scholar]
  34. Kiss Á, Menus Á, Tóth K., Déri M., Sirok D., Gabri E., et al. (2019). Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure. Eur. Arch. Psychiatry Clin. Neurosci. 270 71–82. 10.1007/S00406-018-0975-972 [DOI] [PubMed] [Google Scholar]
  35. Kloosterboer S. M., de Winter B. C. M., Reichart C. G., Kouijzer M. E. J., de Kroon M. M. J., van Daalen E., et al. (2021). Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder. Br. J. Clin. Pharmacol. 87 1069–1081. 10.1111/BCP.14465 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Kubo M., Koue T., Maune H., Fukuda T., Azuma J. (2007). Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab. Pharmacokinet 22 358–366. 10.2133/dmpk.22.358 [DOI] [PubMed] [Google Scholar]
  37. Lane H.-Y., Liu Y.-C., Huang C.-L., Chang Y.-C., Wu P.-L., Lu C.-T., et al. (2006). Risperidone-related weight gain: genetic and nongenetic predictors. J. Clin. Psychopharmacol. 26 128–134. 10.1097/01.jcp.0000203196.65710.2b [DOI] [PubMed] [Google Scholar]
  38. Lee S. T., Ryu S., Kim S. R., Kim M. J., Kim S., Kim J. W., et al. (2012). Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J. Clin. Psychopharmacol. 32 441–448. 10.1097/JCP.0b013e31825ac35c [DOI] [PubMed] [Google Scholar]
  39. Lett T. A. P., Wallace T. J. M., Chowdhury N. I., Tiwari A. K., Kennedy J. L., Müller D. J. (2012). Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol. Psychiatry 17 242–266. 10.1038/mp.2011.109 [DOI] [PubMed] [Google Scholar]
  40. Leucht S., Cipriani A., Spineli L., Mavridis D., Örey D., Richter F., et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382 951–962. [DOI] [PubMed] [Google Scholar]
  41. Leucht S., Tardy M., Komossa K., Heres S., Kissling W., Salanti G., et al. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379 2063–2071. 10.1016/S0140-6736(12)60239-6 [DOI] [PubMed] [Google Scholar]
  42. Lieberman J. A., Stroup T. S., Mcevoy J. P., Swartz M. S., Rosenheck R. A., Perkins D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 1209–1223. [DOI] [PubMed] [Google Scholar]
  43. Lu J., Yang Y., Lu J., Wang Z., He Y., Yan Y., et al. (2021). Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone. BMC Psychiatry 21:70. 10.1186/s12888-020-03034-3039 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Maciukiewicz M., Tiwari A. K., Zai C. C., Gorbovskaya I., Laughlin C. P., Nurmi E. L., et al. (2019). Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans. Schizophr. Res. 212 204–212. 10.1016/J.SCHRES.2019.07.022 [DOI] [PubMed] [Google Scholar]
  45. Martínez-Ortega J. M., Funes-Godoy S., Díaz-Atienza F., Gutiérrez-Rojas L., Pérez-Costillas L., Gurpegui M. (2013). Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur. Child Adolesc. Psychiatry 22 457–479. 10.1007/S00787-013-0399-395 [DOI] [PubMed] [Google Scholar]
  46. Maruf A., Al, Stein K., Arnold P. D., Aitchison K. J., Müller D. J., et al. (2020). CYP2D6 and antipsychotic treatment outcomes in children and youth: a systematic review. J. Child Adolesc. Psychopharmacol. 31 33–45. 10.1089/cap.2020.0093 [DOI] [PubMed] [Google Scholar]
  47. Mihara K., Kondo T., Yasui-Furukori N., Suzuki A., Ishida M., Ono S., et al. (2003). Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther. Drug Monit. 25 287–293. 10.1097/00007691-200306000-200306006 [DOI] [PubMed] [Google Scholar]
  48. Mihara K., Suzuki A., Kondo T., Yasui N., Furukori H., Nagashima U., et al. (2000). Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Ther. Drug Monit. 22 245–249. 10.1097/00007691-200006000-00002 [DOI] [PubMed] [Google Scholar]
  49. Miyamoto S., Miyake N., Jarskog L. F., Fleischhacker W. W., Lieberman J. A. (2012). Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 17 1206–1227. 10.1038/mp.2012.47 [DOI] [PubMed] [Google Scholar]
  50. Muench J., Hamer A. M. (2010). Adverse effects of antipsychotic medications. Am. Fam. Physician 81 617–622. [PubMed] [Google Scholar]
  51. Müller D. J., Kennedy J. L. (2006). Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 7 863–887. 10.2217/14622416.7.6.863 [DOI] [PubMed] [Google Scholar]
  52. Newcomer J. W. (2005). Second-Generation (Atypical) antipsychotics and metabolic effects a comprehensive literature review. CNS Drugs 19 1–93. 10.2165/00023210-200519001-00001 [DOI] [PubMed] [Google Scholar]
  53. Nofziger C., Turner A. J., Sangkuhl K., Whirl-Carrillo M., Agúndez J. A. G., Black J. L., et al. (2020). PharmVar GeneFocus: CYP2D6. Clin. Pharmacol. Ther. 107 154–170. 10.1002/cpt.1643 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Nussbaum L. A., Dumitraşcu V., Tudor A., Grădinaru R., Andreescu N., Puiu M. (2014). Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype. Rom. J. Morphol. Embryol. 55 877–884. [PubMed] [Google Scholar]
  55. Ortega-Vázquez A., Mayen-Lobo Y. G., de Montellano D. J. D.-O., Tristán-López L., Aviña-Cervantes C. L., Ríos C., et al. (2021). Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosis. Drug Dev. Res. 82 685–694. 10.1002/DDR.21774 [DOI] [PubMed] [Google Scholar]
  56. Osborn D. P. J., Limburg H., Walters K., Petersen I., King K., Green J., et al. (2013). Relative incidence of common cancers in people with severe mental illness. Cohort study in the United Kingdom THIN primary care database. Schizophr. Res. 143 44–49. 10.1016/j.schres.2012.11.009 [DOI] [PubMed] [Google Scholar]
  57. Owen R. P., Sangkuhl K., Klein T. E., Altman R. B. (2009). Cytochrome P450 2D6. Pharmacogenet. Genomics 19 559–562. 10.1097/fpc.0b013e32832e0e97 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Ozawa S., Soyama A., Saeki M., Fukushimauesaka H., Itoda M., Koyano S., et al. (2004). Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1 W ABCB1. Drug Metab. Pharmacokin 19 83–95. 10.2133/dmpk.19.83 [DOI] [PubMed] [Google Scholar]
  59. Page M. J., McKenzie J. E., Bossuyt P. M., Boutron I., Hoffmann T. C., Mulrow C. D., et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. 10.1136/BMJ.N71 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Plesnicar B., Zalar B., Breskvar K., Dolzan V. (2006). The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J. Psychopharmacol. 20 829–833. 10.1177/0269881106062894 [DOI] [PubMed] [Google Scholar]
  61. Reynolds G., McGowan O. (2017). Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment. J. Psychopharmacol. 31 1430–1436. 10.1177/0269881117722987 [DOI] [PubMed] [Google Scholar]
  62. Roke Y., Van Harten P. N., Franke B., Galesloot T. E., Boot A. M., Buitelaar J. K. (2013). The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. Pharmacogenet. Genomics 23 487–493. 10.1097/FPC.0B013E3283647C33 [DOI] [PubMed] [Google Scholar]
  63. Sim S. C., Ingelman-Sundberg M. (2013). Update on allele nomenclature for human cytochromes P450 and the human cytochrome P450 allele (CYP-allele) nomenclature database. Methods Mol. Biol. 987 251–259. 10.1007/978-1-62703-321-3_21 [DOI] [PubMed] [Google Scholar]
  64. Simon V., van Winkel R., De Hert M. (2009). Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? a literature review. J. Clin. Psychiatry 70 1041–1050. 10.4088/jcp.08r04392 [DOI] [PubMed] [Google Scholar]
  65. Spina E., De Leon J. (2007). Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin. Pharmacol. Toxicol. 100 4–22. 10.1111/j.1742-7843.2007.00017.x [DOI] [PubMed] [Google Scholar]
  66. Strassnig M., Miewald J., Keshavan M., Ganguli R. (2007). Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr. Res. 93 90–98. 10.1016/J.SCHRES.2007.02.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Subuh Surja A., Reynolds K., Linder M., El-Mallakh R. (2008). Pharmacogenetic testing of CYP2D6 in patients with aripiprazole-related extrapyramidal symptoms: a case-control study. Per. Med. 5 361–365. 10.2217/17410541.5.4.361 [DOI] [PubMed] [Google Scholar]
  68. Sukasem C., Vanwong N., Srisawasdi P., Ngamsamut N., Nuntamool N., Hongkaew Y., et al. (2018). Pharmacogenetics of risperidone-induced insulin resistance in children and adolescents with autism spectrum disorder. Basic Clin. Pharmacol. Toxicol. 23 42–50. 10.1111/bcpt.12970 [DOI] [PubMed] [Google Scholar]
  69. Sun L., McDonnell D., Yu M., Kumar V., von Moltke L. (2019). A phase I Open-Label study to evaluate the effects of rifampin on the pharmacokinetics of olanzapine and samidorphan administered in combination in healthy human subjects. Clin. Drug Investig. 39 477–484. 10.1007/S40261-019-00775-778 [DOI] [PubMed] [Google Scholar]
  70. Suzuki Y., Tsuneyama N., Fukui N., Sugai T., Watanabe J., Ono S., et al. (2014). Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia. Pharmacogenomics J. 14 452–456. 10.1038/tpj.2014.6 [DOI] [PubMed] [Google Scholar]
  71. Swen J. J., Nijenhuis M., De Boer A., Grandia L., Maitland-Van Der, Zee A. H., et al. (2011). Pharmacogenetics: from bench to byte an update of guidelines. Clin. Pharmacol. Ther. 89 662–673. 10.1038/clpt.2011.34 [DOI] [PubMed] [Google Scholar]
  72. Sychev D. A., Zastrozhin M. S., Miroshnichenko I. I., Baymeeva N. V., Smirnov V. V., Grishina E. A., et al. (2017). Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. Drug Metab. Pers. Ther. 32 129–136. 10.1515/dmpt-2017-2021 [DOI] [PubMed] [Google Scholar]
  73. Taipale H., Mittendorfer-Rutz E., Alexanderson K., Majak M., Mehtälä J., Hoti F., et al. (2018). Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr. Res. 197 274–280. 10.1016/J.SCHRES.2017.12.010 [DOI] [PubMed] [Google Scholar]
  74. Taipale H., Tanskanen A., Mehtälä J., Vattulainen P., Correll C. U., Tiihonen J. (2020). 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 19 61–68. 10.1002/WPS.20699 [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Taylor D. M., Barnes T. R. E., Young A. H. (2018). The Maudsley Prescribing Guidelines in Psychiatry, 13th Edn. Hoboken, NJ: Wiley-Blackwell. [Google Scholar]
  76. Taylor D., Barnes T., Young A. (2021). The Maudsley Prescribing Guidelines in Psychiatry, 14th Edn. Hoboken, NJ: Wiley-Blackwell. [Google Scholar]
  77. Tek C., Kucukgoncu S., Guloksuz S., Woods S., Srihari V., Annamalai A. (2016). Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv. Psychiatry 10 193–202. 10.1111/EIP.12251 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. The Cochrone Collaboration (2014). Review Manager (RevMan). London: Cochrone. [Google Scholar]
  79. The Jamovi Project (2021). Jamovi. Available online at: http://www.jamovi.org (accessed February 25, 2021). [Google Scholar]
  80. Theisen F. M., Gebhardt S., Haberhausen M., Heinzel-Gutenbrunner M., Wehmeier P. M., Krieg J.-C., et al. (2005). Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr. Genet. 15 285–289. 10.1097/00041444-200512000-00011 [DOI] [PubMed] [Google Scholar]
  81. Urichuk L., Prior T., Dursun S., Baker G. (2008). Metabolism of atypical antipsychotics: involvement of cytochrome P450 enzymes and relevance for drug-drug interactions. Curr. Drug Metab. 9 410–418. 10.2174/138920008784746373 [DOI] [PubMed] [Google Scholar]
  82. Van Der Weide K., Van Der Weide J. (2015). The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J. Clin. Psychopharmacol. 35 228–236. 10.1097/JCP.0000000000000319 [DOI] [PubMed] [Google Scholar]
  83. Vandenberghe F., Guidi M., Choong E., von Gunten A., Conus P., Csajka C., et al. (2015). Genetics-Based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. Clin. Pharmacokinet. 54 1259–1272. 10.1007/S40262-015-0289-288 [DOI] [PubMed] [Google Scholar]
  84. Vanwong N., Medhasi S., Pongchaidecha M., Ngamsamut N., Pungpetch A., Chamnanphon M., et al. (2014). Pharmacogenetics and clinical risk factors for risperidone-related weight gain in thai autistic spectrum disorder patients. Thai J. Pharmacol. 36 13–25. [Google Scholar]
  85. Viechtbauer W. (2010). Conducting meta-analyses in r with the metafor package. J. Stat. Softw. 36 1–48. 10.18637/JSS.V036.I03 [DOI] [Google Scholar]
  86. Wallace T. J., Zai C. C., Brandl E. J., Müller D. J. (2011). Role of 5-HT2C receptor gene variants in antipsychotic-induced weight gain. Pharmgenom. Pers. Med. 4:83. 10.2147/PGPM.S11866 [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Wishart D. S., Knox C., Guo A. C., Shrivastava S., Hassanali M., Stothard P., et al. (2006). DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34:D668. 10.1093/NAR/GKJ067 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (705.8KB, docx)

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Articles from Frontiers in Psychology are provided here courtesy of Frontiers Media SA

RESOURCES